Navigation Links
Penn researchers demonstrate efficacy of non-Hodgkin's lymphoma vaccine
Date:10/18/2011

PHILADELPHIA An experimental vaccine developed by researchers at the University of Pennsylvania's schools of Medicine and Veterinary Medicine is the first veterinary cancer vaccine of its kind that shows an increase in survival time for dogs with spontaneous non-Hodgkin's lymphoma. The work shows for the first time the feasibility and therapeutic efficacy of this alternative cell-based vaccine, which could be employed in the treatment of a number of different cancer types.

The research was conducted by Nicola Mason, assistant professor of medicine at Penn Vet; Robert H. Vonderheide, associate professor of hematology and oncology at the Perelman School of Medicine; and Karin U. Sorenmo, associate professor of oncology at Penn Vet. Erika Krick, Beth Overley and Thomas P. Gregor of Penn Vet and Christina M. Coughlin of the School of Medicine also contributed to the research.

Their work was published in the open access journal PLOS ONE.

The team recruited dogs that were brought to Penn's Matthew J. Ryan Veterinary Hospital with newly diagnosed non-Hodgkin's lymphoma to receive the experimental vaccine following standard induction chemotherapy and confirmation of clinical remission. The goal of the study was to determine whether the vaccine would prevent or prolong time to a relapse, a common scenario in both humans and dogs with NHL.

"We vaccinated dogs, which were in clinical remission following chemotherapy, three times," Mason said. "We then tracked them over several years to see if the vaccine would prevent relapse and would prolong overall survival.

"We found that, although the vaccinated dogs still relapsed with clinical disease when they were treated with rescue chemotherapy, they had significantly increased overall survival times when compared to an unvaccinated control group. Some of these dogs are still alive and cancer free more than three years later.

"The results with these dogs indicate that our immunotherapy and rescue chemotherapy appear to act synergistically to prevent a second relapse a phenomenon that has been previously recognized in human patients treated with other types of immunotherapy," she said.

Previous cell based vaccines have utilized genetically engineering dendritic cells which are part of the immune system to stimulate immune responses against cancers. Similar to using weakened viruses in traditional vaccines, scientists load these cells with tumor proteins and inject the cells back into the patient's body. Such cell-based vaccines are already being used to treat prostate cancer in humans, but engineering these cells is expensive and time consuming. Furthermore, patients must also endure long, leukapheresis sessions in which the necessary dendritic cells are harvested from their blood.

The Penn team hypothesized that another kind of immune cell, B-cells, could work just as well under the right conditions. Unlike dendritic cells, many B-cells can be grown from a small blood sample, removing the requirement for leukapheresis.

Mason's team made the vaccine by culturing B-cells from the blood taken from the dogs with NHL. These cells were then loaded with RNA that had been isolated from the patient's own tumor.

The results were impressive.

"Though vaccinated and unvaccinated dogs relapsed with clinical disease at the same time, 40 percent of vaccinated dogs that relapsed experienced long-term survival after a second round of chemotherapy; only 7 percent of unvaccinated dogs that relapsed and were treated with the same rescue chemotherapy protocol survived long term," Mason said. "Furthermore, when the vaccinated long-term survivors did eventually die, they showed no evidence of lymphoma on full necropsy."

While the molecular mechanisms responsible for these observed synergistic effects are currently unknown, Mason believes that the vaccine-primed immune system may be boosted by the effects of rescue chemotherapy leading to long term second remissions.

Though the increases in long-term survival are already unprecedented and the proof-of-concept for B-cell-based cancer vaccines represents a step forward in cell-based vaccine development, future research could have even more exciting results.

"These dogs just received three doses of vaccine, three weeks apart. If we kept boosting the immune system in this way by vaccination, perhaps the dogs would not relapse in the first place" Mason said.

Work is now underway to streamline B-cell vaccine generation and initiate further clinical trials aimed at optimizing this novel cell-based approach.


'/>"/>

Contact: Evan Lerner
elerner@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert

Related medicine news :

1. Miriam Hospital researchers pilot new acute hepatitis C screening strategy for HIV-infected patients
2. Researchers discover why steroid treatment for COPD is ineffective
3. Researchers find possible link between bacterium and colon cancer
4. Researchers engineer a new way to inhibit allergic reactions without side effects
5. National Jewish Health researchers awarded $13 million to evaluate treatments for toxic gases
6. Researchers discover hidden genetic influence on cancer
7. Toronto researchers find first physical evidence bilingualism delays onset of Alzheimers symptoms
8. Researchers track number of doctors disciplined and why
9. UCLA researchers develop new way to screen for brain cancer stem cell killers
10. Researchers find race disparity in post-hospital arrival homicide deaths at trauma centers
11. Researchers Assess What Works Best to Prevent PTSD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm ... 7:00pm – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Workrite Ergonomics, ... company that has evolved from humble beginnings to being an internationally recognized leader in ... that we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the ...
(Date:2/10/2016)... ... 2016 , ... Anxiety of older Americans over steep cost increases of prescription ... decade ago, according to The Senior Citizens League (TSCL). Since last ... with rapidly rising costs. “The implications are chilling, particularly for people with chronic ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 09, 2016 , ... ... surgeons are witnessing a dramatic increase in the number of patients under the age ... reflects what they are seeing in their offices, and may indicate an overall shift ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ALSP, Inc. announced that it has appointed Col.(Retired) ... Affairs in preparation for its move into clinical trials with ... stated, "We are pleased to welcome Dallas Hack ... an individual of such practical knowledge and far-reaching experience in ... on his broad experience and success as a clinician and ...
(Date:2/10/2016)... 2016 Intouch Solutions, a leading marketing agency ... trend regarding the evolution of digital sales aids ... deliver compelling sales presentations via tablets. After conducting ... 2015, Intouch uncovered that while most pharmaceutical representatives ... many are not using them effectively during physician ...
(Date:2/10/2016)... -- Until recently, the options for reducing the appearance of ... approved the non-invasive Coolsculpting treatment, which removes fat cells ... in 2010 for the abdomen and this approval was ... this add-on approval, the experts at Laser Therapy Health ... CoolMini, to address smaller areas of fat. ...
Breaking Medicine Technology: